Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer (Englisch)
- Neue Suche nach: Ruiz, M.
- Neue Suche nach: Salvador, J.
- Neue Suche nach: Bayo, J.
- Neue Suche nach: Lomas, M.
- Neue Suche nach: Moreno, A.
- Neue Suche nach: Valero, M.
- Neue Suche nach: Bernabé, R.
- Neue Suche nach: Vicente, D.
- Neue Suche nach: Jiménez, J.
- Neue Suche nach: Lopez-Ladrón, A.
- Neue Suche nach: Ruiz, M.
- Neue Suche nach: Salvador, J.
- Neue Suche nach: Bayo, J.
- Neue Suche nach: Lomas, M.
- Neue Suche nach: Moreno, A.
- Neue Suche nach: Valero, M.
- Neue Suche nach: Bernabé, R.
- Neue Suche nach: Vicente, D.
- Neue Suche nach: Jiménez, J.
- Neue Suche nach: Lopez-Ladrón, A.
In:
CANCER CHEMOTHERAPY AND PHARMACOLOGY
;
62
, 6
;
1085-1090
;
2008
-
ISSN:
- Aufsatz (Zeitschrift) / Print
-
Titel:Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer
-
Beteiligte:Ruiz, M. ( Autor:in ) / Salvador, J. ( Autor:in ) / Bayo, J. ( Autor:in ) / Lomas, M. ( Autor:in ) / Moreno, A. ( Autor:in ) / Valero, M. ( Autor:in ) / Bernabé, R. ( Autor:in ) / Vicente, D. ( Autor:in ) / Jiménez, J. ( Autor:in ) / Lopez-Ladrón, A. ( Autor:in )
-
Erschienen in:CANCER CHEMOTHERAPY AND PHARMACOLOGY ; 62, 6 ; 1085-1090
-
Verlag:
- Neue Suche nach: Springer Science + Business Media
-
Erscheinungsdatum:01.01.2008
-
Format / Umfang:6 pages
-
ISSN:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Print
-
Sprache:Englisch
- Neue Suche nach: 615.58
- Weitere Informationen zu Dewey Decimal Classification
-
Klassifikation:
DDC: 615.58 -
Datenquelle:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Inhaltsverzeichnis – Band 62, Ausgabe 6
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 931
-
Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II studyFrançois, E. / Berdah, J. F. / Chamorey, E. / Lesbats, G. r. / Teissier, E. / Codoul, J. F. / Badetti, J. L. / Hébert, C. / Mari, V. r. et al. | 2008
- 937
-
Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivoMauritz, R. / Peters, G. J. / Kathmann, I. / Teshale, H. / Noordhuis, P. / Comijn, E. M. / Pinedo, H. M. / Jansen, G. et al. | 2008
- 949
-
Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasionXie, Z. / Choong, P. F. / Poon, L. F. / Zhou, J. / Khng, J. / Jasinghe, V. J. / Palaniyandi, S. / Chen, C. S. et al. | 2008
- 959
-
Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapyNagai, H. / Miyaki, D. / Matsui, T. / Kanayama, M. / Higami, K. / Momiyama, K. / Ikehara, T. / Watanabe, M. / Sumino, Y. / Miki, K. et al. | 2008
- 965
-
BRCA1 transcriptional activity is enhanced by interactions between its AD1 domain and AhRKang, H. J. / Kim, H. J. / Cho, C. H. / Hu, Y. / Li, R. / Bae, I. et al. | 2008
- 977
-
Disruption of microfilaments by cytochalasin B decreases accumulation of cisplatin in human epidermal carcinoma and liver carcinoma cell linesLiang, X. J. / Yin, J. J. / Taylor, B. / Winkovitch, S. M. / Garfield, S. H. / Shen, D. W. / Gottesman, M. M. / Aszalos, A. et al. | 2008
- 985
-
Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor modelCao, X. / Jia, G. / Zhang, T. / Yang, M. / Wang, B. / Wassenaar, P. A. / Cheng, H. / Knopp, M. V. / Sun, D. et al. | 2008
- 995
-
Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activityCallizot, N. / Andriambeloson, E. / Glass, J. / Revel, M. / Ferro, P. / Cirillo, R. / Vitte, P. A. / Dreano, M. et al. | 2008
- 1009
-
Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancerPark, S. H. / Cho, E. K. / Kim, Y. / Kyung, S. Y. / An, C. H. / Lee, S. P. / Park, J. W. / Jeong, S. H. / Lee, J. I. / Choi, S. J. et al. | 2008
- 1015
-
Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus SchizandraeHuang, M. / Jin, J. / Sun, H. / Liu, G. T. et al. | 2008
- 1027
-
Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children’s oncology groupThompson, P. A. / Gupta, M. / Rosner, G. L. / Yu, A. / Barrett, J. / Bomgaars, L. / Bernstein, M. L. / Blaney, S. M. / Mondick, J. et al. | 2008
- 1039
-
Topotecan distribution in an anephric infant with therapy resistant bilateral Wilms tumor with a novel germline WT1 gene mutationLugtenberg, R. T. / Cransberg, K. / Loos, W. J. / Wagner, A. / Alders, M. / Heuvel-Eibrink, M. M. et al. | 2008
- 1045
-
Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivoO’Reilly, T. / Wartmann, M. / Brueggen, J. / Allegrini, P. R. / Floersheimer, A. / Maira, M. / McSheehy, P. M. et al. | 2008
- 1055
-
Inducing apoptosis and enhancing chemosensitivity to Gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cellWei, S. H. / Dong, K. / Lin, F. / Wang, X. / Li, B. / Shen, J. j. / Zhang, Q. / Wang, R. / Zhang, H. Z. et al. | 2008
- 1065
-
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitorLuo, F. R. / Barrett, Y. C. / Yang, Z. / Camuso, A. / McGlinchey, K. / Wen, M. L. / Smykla, R. / Fager, K. / Wild, R. / Palme, H. et al. | 2008
- 1075
-
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphismsFont, A. / Salazar, R. / Maurel, J. / Taron, M. / Ramirez, J. L. / Tabernero, J. / Gallego, R. / Casado, E. / Manzano, J. L. / Carcereny, E. et al. | 2008
- 1085
-
Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancerRuiz, M. / Salvador, J. / Bayo, J. / Lomas, M. / Moreno, A. / Valero, M. / Bernabé, R. / Vicente, D. / Jiménez, J. / Lopez-Ladrón, A. et al. | 2008
- 1091
-
Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusionBrown, A. P. / Courtney, C. L. / Criswell, K. A. / Holliman, C. L. / Evering, W. / Jessen, B. A. et al. | 2008
- 1103
-
A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancerNakajo, A. / Hokita, S. / Ishigami, S. / Miyazono, F. / Etoh, T. / Hamanoue, M. / Maenohara, S. / Iwashita, T. / Komatsu, H. / Satoh, K. et al. | 2008
- 1111
-
Tumor resensitization to erlotinib following brief substitution of cetuximabEpstein, R. J. / Leung, T. W. et al. | 2008
- 1113
-
Is oncogenesis a normal cellular defense mechanism?Sorscher, S. / Hill, A. E. / Sorscher, E. J. et al. | 2008
- 1115
-
Professor Lloyd R. Kelland: man of scienceNewell, H. / McKeage, M. / Stanway, C. et al. | 2008